Vaccination againstKlebsiella aerogenes

Abstract

SummaryKlebsiella vaccine was prepared from strains ofKlebsiella aerogeneswith capsular types Kl, K36, K44 and K Cross (a type which cross-reactsin vitrowith sera from many klebsiella capsular types). The vaccine was extracted by dialysis and ultrafiltration from capsular material released during growth of the bacteria in a five-day batch culture.Mice given one dose of vaccine from K1a (l·0 μg/mouse) survived lethal intraperitoneal challenge of 11/11 homologous klebsiella strains four days after vaccination; 14 days after vaccination protection against the same challenge strains had declined to 5/11 strains. Vaccines from Kla, b, c, K3G, K44 and K Cross induced homologous protection and protected mice against different ranges of heterologous klebsiella capsular types.The protective response of the mice was greatly enhanced by administering three doses of the vaccines. Vaccines from Kl, K36, K44 and K Cross protected mice against 14/20, 11/20, 10/20 and 9/20 homologous and heterologous klebsiella challenge strains respectively.None of the klebsiella vaccines was toxic for mice at the immunizing dose (l·0 μg/mouse). Vaccine from K36 was the most lethal, killing mice at 103immunizing doses. The least toxic vaccine was from K44, which killed mice at 104immunizing doses.

Phagocytosis and Killing of Carbapenem-Resistant ST258Klebsiella pneumoniaeby Human Neutrophils

“…Alternative approaches to prevention and treatment of infections, such as an active and/or passive vaccine, are needed. Vaccine approaches for protection against Klebsiella infections were reported extensively in the 1980s [39][40][41][42][43][44], but the organisms predated the contemporary carbapenem-resistant ST258 strains. Morerecent studies tested immunogenicity and safety of a capsular polysaccharide vaccine against Klebsiella [45].…”

Production of an extracellular toxic complex by various strains of Klebsiella pneumoniae

“…Immunization with the ETC of KP2 2-70 induced protection in mice against homologous KP2 2-70 organisms (Table 2). This was not surprising in light of the studies which have shown that purified CPS of K. pneumoniae can elicit the production of protective antibody (3,14,24). What was surprising was the finding that immunization with the KP2 2-70 ETC would protect experimental animals against a heterologous organism (Table 2).…”

“…What was surprising was the finding that immunization with the KP2 2-70 ETC would protect experimental animals against a heterologous organism (Table 2). Protection produced by Klebsiella capsular vaccines has, for the most part, been thought to be type specific (2), although Roe and Jones (14,24) have reported heterologous protection using Klebsiella CPS vaccines. Because all the K. pneumoniae strains that I utilized in this study possessed the serotype 1 0 antigen, it is most probable that the protective antibody was directed against the 0 (LPS) antigen.…”

“…The induced protection appears to be antibody mediated since antibody to the ETC passively protected experimental animals against homologous ETC and homologous K. pneumoniae (Table 3). Although it seems fairly well established that immunization of experimental animals with Klebsiella CPS can induce protection against homologous and heterologous K. pneumoniae (2,3,14,24), the effect(s) of immunization with K. pneumoniae LPS seems less clear. Riottot et al (22) and Fournier et al (8) felt that antibody to LPS appeared to play no role in protection in experiments in which immunization of mice with ribosomal vaccines provided good serotype-specific protection.…”

Progress towards the development of Klebsiella vaccines

“…belonging to 71 different K antigen serogroups [58], but the protection was often short-lived (<14 days). A quadrivalent vaccine showed cross-reaction to many Klebsiella capsular types [59].…”